Matteo Bassetti1,2, Maddalena Peghin1, Alessia Carnelutti1, Elda Righi1. 1. Infectious Disease Division, Azienda Sanitaria Universitaria Integrata, Presidio Ospedaliero Universitario Santa Maria della Misericordia. 2. Department of Medicine, Infectious Diseases Clinic, University of Udine, Udine, Italy.
Abstract
PURPOSE OF REVIEW: The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting. Staphylococcus aureus is the most frequently isolated pathogen, and the rise in infections due to methicillin-resistant Staphylococcus aureus (MRSA) has been associated with inadequate antibiotic treatment and increased morbidity. RECENT FINDINGS: A number of new antimicrobials with activity against drug-resistant Gram-positive pathogens, including MRSA, have been recently approved for the treatment of SSTIs. New lipoglycopeptides, in particular dalbavancin, are long-acting antibiotics with potential for infrequent administration, offering the possibility for outpatient treatment and early hospital discharge. SUMMARY: Dalbavancin is a new lipoglycopeptide showing high activity against Gram-positive bacteria, including drug-resistant strains. Dalbavancin presents a distinctive pharmacokinetic profile with a terminal prolonged half-life of approximately 14 days. This characteristic allows once-weekly dosing interval, avoiding the need for daily dosing and offering an advantage over other compounds for potential use in the outpatient setting or to promote early hospital discharge. Dalbavancin has a favorable adverse effect profile and appears to be a promising new alternative for treatment of SSTIs. We have reviewed the pharmacokinetic properties of dalbavancin and the clinical evidence for its use in complicated SSTIs and other potential applications.
PURPOSE OF REVIEW: The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting. Staphylococcus aureus is the most frequently isolated pathogen, and the rise in infections due to methicillin-resistant Staphylococcus aureus (MRSA) has been associated with inadequate antibiotic treatment and increased morbidity. RECENT FINDINGS: A number of new antimicrobials with activity against drug-resistant Gram-positive pathogens, including MRSA, have been recently approved for the treatment of SSTIs. New lipoglycopeptides, in particular dalbavancin, are long-acting antibiotics with potential for infrequent administration, offering the possibility for outpatient treatment and early hospital discharge. SUMMARY:Dalbavancin is a new lipoglycopeptide showing high activity against Gram-positive bacteria, including drug-resistant strains. Dalbavancin presents a distinctive pharmacokinetic profile with a terminal prolonged half-life of approximately 14 days. This characteristic allows once-weekly dosing interval, avoiding the need for daily dosing and offering an advantage over other compounds for potential use in the outpatient setting or to promote early hospital discharge. Dalbavancin has a favorable adverse effect profile and appears to be a promising new alternative for treatment of SSTIs. We have reviewed the pharmacokinetic properties of dalbavancin and the clinical evidence for its use in complicated SSTIs and other potential applications.
Authors: Massimo Sartelli; Xavier Guirao; Timothy C Hardcastle; Yoram Kluger; Marja A Boermeester; Kemal Raşa; Luca Ansaloni; Federico Coccolini; Philippe Montravers; Fikri M Abu-Zidan; Michele Bartoletti; Matteo Bassetti; Offir Ben-Ishay; Walter L Biffl; Osvaldo Chiara; Massimo Chiarugi; Raul Coimbra; Francesco Giuseppe De Rosa; Belinda De Simone; Salomone Di Saverio; Maddalena Giannella; George Gkiokas; Vladimir Khokha; Francesco M Labricciosa; Ari Leppäniemi; Andrey Litvin; Ernest E Moore; Ionut Negoi; Leonardo Pagani; Maddalena Peghin; Edoardo Picetti; Tadeja Pintar; Guntars Pupelis; Ines Rubio-Perez; Boris Sakakushev; Helmut Segovia-Lohse; Gabriele Sganga; Vishal Shelat; Michael Sugrue; Antonio Tarasconi; Cristian Tranà; Jan Ulrych; Pierluigi Viale; Fausto Catena Journal: World J Emerg Surg Date: 2018-12-14 Impact factor: 5.469
Authors: L Buzón Martín; M Mora Fernández; J M Perales Ruiz; M Ortega Lafont; L Álvarez Paredes; M A Morán Rodríguez; M Fernández Regueras; M A Machín Morón; G Mejías Lobón Journal: Rev Esp Quimioter Date: 2019-10-22 Impact factor: 1.553
Authors: Massimo Sartelli; Federico Coccolini; Yoram Kluger; Ervis Agastra; Fikri M Abu-Zidan; Ashraf El Sayed Abbas; Luca Ansaloni; Abdulrashid Kayode Adesunkanmi; Goran Augustin; Miklosh Bala; Oussama Baraket; Walter L Biffl; Marco Ceresoli; Elisabetta Cerutti; Osvaldo Chiara; Enrico Cicuttin; Massimo Chiarugi; Raul Coimbra; Daniela Corsi; Francesco Cortese; Yunfeng Cui; Dimitris Damaskos; Nicola de'Angelis; Samir Delibegovic; Zaza Demetrashvili; Belinda De Simone; Stijn W de Jonge; Stefano Di Bella; Salomone Di Saverio; Therese M Duane; Paola Fugazzola; Joseph M Galante; Wagih Ghnnam; George Gkiokas; Carlos Augusto Gomes; Ewen A Griffiths; Timothy C Hardcastle; Andreas Hecker; Torsten Herzog; Aleksandar Karamarkovic; Vladimir Khokha; Peter K Kim; Jae Il Kim; Andrew W Kirkpatrick; Victor Kong; Renol M Koshy; Kenji Inaba; Arda Isik; Rao Ivatury; Francesco M Labricciosa; Yeong Yeh Lee; Ari Leppäniemi; Andrey Litvin; Davide Luppi; Ronald V Maier; Athanasios Marinis; Sanjay Marwah; Cristian Mesina; Ernest E Moore; Frederick A Moore; Ionut Negoi; Iyiade Olaoye; Carlos A Ordoñez; Mouaqit Ouadii; Andrew B Peitzman; Gennaro Perrone; Tadeja Pintar; Giuseppe Pipitone; Mauro Podda; Kemal Raşa; Julival Ribeiro; Gabriel Rodrigues; Ines Rubio-Perez; Ibrahima Sall; Norio Sato; Robert G Sawyer; Vishal G Shelat; Michael Sugrue; Antonio Tarasconi; Matti Tolonen; Bruno Viaggi; Andrea Celotti; Claudio Casella; Leonardo Pagani; Sameer Dhingra; Gian Luca Baiocchi; Fausto Catena Journal: World J Emerg Surg Date: 2022-01-15 Impact factor: 5.469
Authors: Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza Journal: Front Cell Infect Microbiol Date: 2020-07-07 Impact factor: 5.293